Starting with a Higher Dose of Inhaled Corticosteroids in Primary Care Asthma Treatment

Starting with a Higher Dose of Inhaled Corticosteroids in Primary Care Asthma Treatment THYS van der MOLEN, BETTY MEYBOOM-DE JONG, HELMA H. MULDER, and DIRKJE S. POSTMA Department of General Practice, University of Groningen, and Department of Pulmonary Diseases, University Hospital, Groningen, The Netherlands New British guidelines on the treatment of asthma (9) advocate starting with a higher dose of inhaled corticosteroids in newly detected asthma patients. We investigated whether initiating inhaled steroid treatment with a higher dose is clinically more effective than a lower dose in steroid naive patients with asthma. The study had a 13-wk randomized, double-blind, parallel design: 1-mo treatment with 400 g budesonide twice a day, or 100 g budesonide twice a day by dry powder inhaler, and follow-up treatment period of 2 mo with 200 g budesonide once daily for all patients. Forty patients started with 400 g budesonide twice daily, 44 with 100 g budesonide twice daily. Mean age was 32 yr, baseline FEV 1 value 84% predicted, reversibility 9% from baseline, and mean bronchodilator use 1.6 inhalations/d in the run-in period. After 4 wk of treatment with 400 g and 100 g budesonide twice daily mean morning peak expiratory flow (PEF) increased 27 L/min (SD 50), and 38 L/ min (SD 53), respectively (p 0.30); mean symptom score improved from 1.1 to 0.6 and from 1.1 to 0.5. These effects were maintained in the 2 mo follow-up. This study suggests that starting inhaled corticosteroids at a higher dose is not superior to a lower dose in the treatment of newly detected asthma. van der Molen T, Meyboom-de Jong B, Mulder HH, Postma DS. Starting with a higher dose of inhaled corticosteroids in primary care asthma treatment. AM J RESPIR CRIT CARE MED 1998;158:121 125. (Received in original form July 8, 1997 and in revised form February 25, 1998) Supported by Astra The Netherlands. Correspondence and requests for reprints should be addressed to T. van der Molen, Department of General Practice, Antonius Deusinglaan 4, 9713 AW Groningen, The Netherlands. Am J Respir Crit Care Med Vol 158. pp 121 125, 1998 Internet address: www.atsjournals.org Inhaled corticosteroids are very effective to control symptoms in the treatment of asthma (1, 2). Current guidelines on the management of asthma advocate inhaled corticosteroid therapy as soon as more than 3 doses per week of an inhaled bronchodilator are needed for symptom relief (3 5). General practitioners in many countries have adopted these guidelines and early treatment of asthma with inhaled corticosteroids has become the golden therapy standard. Most guidelines suggest a step-up treatment, i.e., to start at a low dose and increase the dose progressively until asthma control is achieved (3 5). The suggested starting doses are based on clinical studies with conflicting outcome with regard to a dose-related effect of inhaled corticosteroids (6 8). The new British guidelines on the treatment of asthma (9, 10) advocate a step-down treatment with inhaled corticosteroids starting with 800 g of inhaled corticosteroids daily in patients with asthma, including patients with mild asthma as detected in a general practitioner setting. This recommendation stems from clinical practice and common sense, and just as with a step-up treatment it is not based on the outcome of clinical studies (9, 11). Until now no formal trials have been published to assess whether step-down treatment is effective. Support for the step-down approach originates only from studies that demonstrate that the dose of inhaled steroids can be reduced once control is achieved (12, 13). We designed a study to investigate whether step down treatment with inhaled corticosteroids (starting with 400 g budesonide twice a day in contrast to 100 g budesonide twice a day), in steroid-naive asthma patients would be more effective in improving lung function and symptoms. Additionally, we aimed to investigate whether a maintenance treatment with 200 g of inhaled corticosteroids, inhaled once daily, could maintain the induced effect of the previous treatment. We consider this to be the step-down treatment of inhaled corticosteroids in contrast to low-dose maintenance treatment. METHODS Patients Patients were selected in 25 general practices. They were diagnosed as having asthma according to the definition of the Dutch College for General Practice by their general practitioner (3). All patients were between 18 and 50 yr of age, had a prebronchodilator PEF and FEV 1 50% of predicted, and reported a weekly need for 3 doses or more of an inhaled bronchodilator in the month before enrollment. Excluded were patients with a smoking history of more than 20 pack-years, those who received steroid treatment or had an exacerbation of their asthma in the 2 mo prior to enrollment as well as patients with serious concomitant disease. The study protocol was reviewed and approved by the medical ethics committee of the University Hospital of Groningen. All patients were informed orally and in writing of the purpose of the study and signed an informed consent form. Study Design The study had a double-blind, randomized, parallel design. A total of 91 patients were selected from July 1994 to May 1995. After a run-in period of 1 wk on bronchodilator therapy (terbutaline via Turbuhaler,

122 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 158 1998 250 g per dose) if needed, patients were either randomized to double-blind treatment with 400 g budesonide via Turbuhaler (Astra Pharmaceutica, Zoetermeer, The Netherlands) twice daily or to 100 g budesonide twice daily for 4 wk. Hereafter, all patients were treated with 200 g budesonide once daily (in the morning) for another 8 wk. Inhaled bronchodilators were only used when needed. Throughout the study, patients completed a diary twice daily, recording PEF (standing, best of three attempts; mini-vitalograph, absolute scale; Vitalograph, Buckingham, UK), daytime symptoms (0 none; 1 mild, aware of symptoms, but easily tolerated; 2 moderate, some discomfort, causing interference with daily life; 3 severe, incapacitating, inability to work or do usual activities), nighttime symptoms (0 not waking up because of asthma; 1 awoke because of asthma and/or a bronchodilator had to be used at night), and medication use. Before and after the run-in period and after 1, 4, 8, and 12 wk of treatment the general practitioner measured the patient s lung function (FEV 1, vital capacity [VC], and PEF, by Microspiro 3300; Sensor Medics, Bilthoven, The Netherlands), at approximately the same time of day. Lung function data are expressed as percentage of predicted normal (14). On all five visits, the physician asked the patient to report adverse events. Analysis The primary objective of the study was to assess the efficacy of the different dosages of budesonide. The primary efficacy variable was morning PEF, recorded at home. All assessments were analyzed by a twoway fixed effects analysis of variance of the change from baseline. The original 25 centers were pooled into seven new centers of approximately the same size. For all diary assessments (morning PEF, evening PEF, PEF fall overnight, terbutaline use, daytime and nighttime symptoms) means were calculated over the last 7 d before each visit. FEV 1 values obtained at randomization are the baseline values in the analyses. For each patient the time to reach optimal asthma control was calculated, defined as the number of days after randomization until at least three of the five following criteria were met during a period of 7 consecutive days: (1) no symptoms at night; (2) 50% reduction in daytime asthma symptoms compared with run-in; (3) 50% reduction in terbutaline use compared with run-in; (4) morning PEF values 120% of run-in; (5) fall in PEF overnight 75% of run-in. p Values refer to two-sided significance levels. All calculations were based on the all patients treated approach. Results are expressed as mean SD and with 95% confidence intervals (CI). Compliance with medication intake was calculated from the notations in the diary cards. The patient was considered to be compliant, if 75% to 125% of the doses were reported to have been used. Power analysis prior to the study revealed that with 80 patients in the study a clinically relevant difference of 30 L/min in morning PEF could be detected with a power of 80% at the p 0.05 level, assuming a SD in the change from baseline in PEF of 50 L/min. TABLE 1 PATIENT CHARACTERISTICS OF THE GROUPS RECEIVING 400 g BUDESONIDE TWICE DAILY AND 100 g BUDESONIDE TWICE DAILY* 400 g b.i.d. 100 g b.i.d. Subjects 40 44 Male, n 18 19 Age, yr 31.3 (10.8) 32.0 (8.1) Current smoking, n 16 16 FEV 1, L 3.09 (0.70) 3.16 (0.79) FEV 1, % pred 83.1 (13.9) 85.1 (17.1) Reversibility, % baseline 7.8 (9.5) 10.9 (8.9) Run-in values PEF morning, L/min 399 (100) 397 (97) PEF evening, L/min 427 (89) 437 (99) Symptom score/d (max 3) 1.13 (0.59) 1.05 (0.61) Awakenings/night 0.24 (0.31) 0.31 (0.32) Rescue inhalations/d 1.58 (1.43) 1.57 (1.31) * SD in parentheses. the next 8 wk with once daily treatment compliance was 89%. No patient was noted to have used more than 125% of prescribed budesonide doses, but 16 patients reported less than 75% reported doses on one or more periods. Five patients started to use nonallowed medication, in three cases because of an asthma exacerbation. Pharmacologically predictable adverse events were infrequently reported, i.e., a mild hoarseness by one patient in each group, other throat complaints by three patients starting with 400 g twice a day and by two patients starting with 100 g twice a day. Oropharyngeal candidiasis was not observed. No serious adverse events were reported. Diary Morning PEF increased slightly during the first week with 400 g budesonide twice daily treatment (4 L/min), but significantly more during 100 g budesonide twice a day (24 L/min), mean difference being 20.6 L/min, 95% CI 3.4 to 37.9 L/min, p 0.02 (Figure 1). In the fourth week of treatment there was RESULTS Of the 91 enrolled patients, seven were not randomized, three because they were not compliant, two because of a deterioration of asthma, and two because of withdrawal of consent. Characteristics of the 40 patients randomized to the 100 g budesonide twice daily starting dose and of the 44 patients to the 400 g budesonide twice daily starting dose are shown in Table 1. Twelve patients used additional medication besides an inhaled bronchodilator prior to the study, mainly cromoglycate. Six patients in the 400 g twice daily and five patients in the 100 g twice daily group did not complete the study according to the protocol four because of unwillingness to continue, two because of adverse events, two because of deterioration of asthma, one ran away from home, one did not attend the visits on the scheduled times, and in one case an error was made in dispensing the study medication. Compliance with study drug intake was good. On average 93% of the morning doses and 91% of the evening doses were reported to have been taken in the first 4 wk of the treatment period. In Figure 1. Changes in morning PEF from run-in period after 1 wk and 4 wk of treatment with 100 g budesonide and 400 g budesonide twice daily, after 8 wk and 12 wk of treatment on 200 g budesonide once daily.

van der Molen, Meyboom-de Jong, Mulder, et al.: Inhaled Corticosteroids in Asthma 123 no significant difference in the change from baseline value in morning PEF (27 respectively 38 L/min, p 0.30). Also in the next 8 wk of once-daily treatment, no significant difference between both groups was found. Evening PEF values were less increased than morning values, and changes from baseline were not significantly different between groups. PEF variation decreased similarly in the two groups. During the run-in period, patients were mildly symptomatic with average daytime asthma symptoms 1.1 on a scale from 0 to 3. Patients nevertheless reported nocturnal awakenings and/or nocturnal medication intake in 27% of the nights. Both treatment groups reported fewest nocturnal complaints in the fourth treatment week (in 13% of the nights) with a small deterioration over the ensuing 8 wk (difference between groups not significant). Daytime symptoms were approximately reduced by 50% after 4 wk of treatment, and stayed low throughout the remainder of the study (difference between groups not significant) (Figure 2). In the run-in period, patients were observed to have used 1.5 doses of bronchodilator per day. During treatment with budesonide this was reduced by 38% compared with the run-in period, in patients starting with 400 g budesonide twice a day and by 48% in those starting with 100 g budesonide twice a day (difference between groups not significant) (Figure 3). The time to reach optimal asthma control could not be calculated in 25 patients, because they either never had a period of 7 consecutive days with completed diary data or never reached this predetermined optimal control (Figure 4). Median time to reach optimal asthma control was 15 d in the 400 g budesonide twice daily group (n 26) and 20 d in the 100 g budesonide twice daily group (n 33, difference not significant). Spirometry At enrollment, mean FEV 1, measured by the GPs in their offices, was 84% of predicted. One-week treatment induced an increase in FEV 1 predicted of 2.2% with 400 g budesonide twice a day and 1.2% with 100 g budesonide twice a day. The maximal effect on FEV 1 was reached after 4 wk, with no changes thereafter. All differences between the two treatments were not statistically significant. DISCUSSION In the present study, we show no advantage of starting treatment with 400 g budesonide twice a day above 100 g budesonide twice a day in steroid-naive asthmatic patients recruited in general practice. This finding is very important for day-today asthma management in general practice and contrasts with U.K. guidelines on the treatment of asthma, advocating a step-down treatment in steroid-naive asthma patients (10). The present study shows that 200 g daily of budesonide as starting and maintenance dose is sufficient to control asthma in the majority of steroid-naive asthma patients. A minority of patients, equally divided (27%) over both treatment groups, did not reach optimal asthma control following the predetermined criteria. The explanation for this phenomenon is that three of the five criteria were related to marked improvements in morning PEF to 120% of baseline, a 50% reduction in daytime asthma symptoms, and a 50% reduction in terbutaline use as compared with the run-in period. These improvements were difficult to meet in patients already experiencing few symptoms and near-normal baseline values during run-in. Other patients failed to complete sufficient diary data to complete a period of 7 consecutive days during the treatment period in which they reached the predetermined criteria. With other criteria, a higher number of sufficient asthma control could be shown, but without changing the main conclusion of the study that both treatment strategies were equally effective in this group of patients. These findings seem to be in contrast to a number of other studies showing a clear dose-dependent treatment effect on airway hyperresponsiveness, and a smaller dose dependent effect on symptoms and lung function (15 17). In a study from Kraan and coworkers (6), starting inhaled corticosteroids with a high dose (400 g budesonide twice daily) induced a more rapid and larger improvement in bronchial hyperresponsiveness than a lower dose (100 g budesonide twice daily) in a group of patients with mild asthma (mean FEV 1 84% predicted) who were referred to a hospital outpatient clinic. However, symptom scores did not differ between the groups. In patients with more severe asthma (mean FEV 1 62% predicted), a dose-related effect on lung function and symptom scores has Figure 2. Changes in daytime symptoms from baseline during run-in period, after 1 wk and 4 wk of treatment with 100 g budesonide twice daily and 400 g budesonide, after 8 wk and 12 wk of treatment on 200 g budesonide once daily. Figure 3. Changes in bronchodilator use from baseline during runin period, after 1 wk and 4 wk of treatment with 100 g budesonide twice daily and 400 g budesonide twice daily, after 8 wk and 12 wk of treatment on 200 g budesonide once daily.

124 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 158 1998 Figure 4. Proportion of patients and time of reaching asthma control according to predetermined criteria in two treatment groups of 100 g budesonide twice daily, 400 g budesonide twice daily, and maintenance treatment period on 200 g once daily. been observed (18). In a study by Lorentzson (8) in an outpatient setting patients with mild asthma (mean morning PEF around 80% predicted) benefitted from 200 g budesonide once daily. These studies indicate that the dose-related effect of inhaled corticosteroids on symptoms and lung function depends partly on the severity of asthma and disappears in mild or moderate asthma. However, the effect of inhaled corticosteroids on bronchial hyperresponsiveness seems to be doserelated even in relatively mild asthma (7). There has been much debate about the potency of different inhaled corticosteroids and the influence of the inhalation device on the effect of inhaled corticosteroids (19). Due to possible differences in potency between beclomethasone diproprionate, budesonide, and fluticasone (20, 21), it is hard to establish a standardized starting dose for all three steroids. However, there is evidence that the inhalation device has an important influence on the lung deposition and the effect of inhaled corticosteroids (19). The lung deposition of the dry powder inhaler Turbuhaler is twice that from pressurized metered dose inhalers (PMDI) (22). The 100 g budesonide twice daily via turbuhaler used in this study possibly could therefore be as potent as 200 g twice daily via PMDI, the starting dose advocated by current guidelines (3, 5). After changing from either dose in the first month, 400 g budesonide twice daily and 100 g twice daily, to 200 g budesonide once daily there was no deterioration detectable in diary parameters or lung function. Our patients, with mild asthma as judged from their FEV 1 being 84% predicted, still benefitted from inhaled corticosteroid treatment because the increase in PEF was 25 to 30 L/min (8 to 9% above baseline values). This improvement was as large as the increase in PEF, seen during the reversibility test at enrollment in the study. Symptom scores and concomitant medication use were greatly diminished within weeks, even though the lung function parameter FEV 1, as measured at the visits to the GP, improved only to a small extent. Thus, low-dose inhaled corticosteroids, 200 g budesonide once daily, was enough in the treatment of our asthma patients. Further studies are needed to determine whether this is the lowest dosage to establish an effective treatment in patients with mild to moderate asthma. We conclude that in general practice most newly treated asthma patients react with quick control of asthma symptoms on low-dose inhaled corticosteroids (100 g budesonide twice a day). Furthermore, the patients in our study did not experience an extra benefit from an initial high dose of inhaled corticosteroids (400 g budesonide twice daily). References 1. Barnes, P. J., and S. Pederson. 1993. Efficacy and safety of inhaled corticosteroids in asthma. Am. Rev. Respir. Dis. 148:S1 S26. 2. Kerstjens, H. A. M., P. L. P. Brand, and D. S. Postma. 1993. Bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease [reply to letters]. N. Engl. J. Med. 328:1044 1045. 3. Bottema, B. J. A. M., E. J. Fabels, and P. M. van Grunsven. 1992. NHGstandaard Cara bij volwassenen: diagnostiek. Huisarts en Wetenschap 35:430 436. 4. Statement by the British Thoracic Society, the British Paediatric Association, the Research Unit of the Royal College of Physicians of London, the King s Fund Centre, the National Asthma Campaign, the Royal College of General Practitioners, the General Practitioners in Asthma Group, the British Association of Accident and Emergency Medicine, and the British Paediatric Respiratory Group. 1993. Guidelines on the management of asthma. Thorax 48(Suppl.):S1 S24. 5. International Asthma Management Project. 1992. International consensus report on the diagnosis and treatment of asthma. NHLBI, NIH, Bethesda, MD. Publication No. 92-3091. 6. Kraan, J., G. H. Koëter, Th. W. van der Mark, H. J. Sluiter, and K. de Vries. 1985. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J. Allergy Clin. Immunol. 76:628 636. 7. Johansson, S. A., and R. Dahl. 1998. A double blind dose response study of budesonide by inhalation in patients with bronchial asthma. Allergy 43:173 178.

van der Molen, Meyboom-de Jong, Mulder, et al.: Inhaled Corticosteroids in Asthma 125 8. Lorentzson, S., J. Boe, G. Eriksson, and G. Persson. 1990. Use of inhaled corticosteroids in patients with mild asthma. Thorax 45:733 735. 9. British Asthma Guidelines Coordinating Committee. 1997. British guidelines on asthma management: 1995 review and position statement. Thorax 52:S1 S24. 10. Barnes, P. J. 1996. Inhaled glucocorticoids: new developments relevant to updating of the asthma management guidelines. Respir. Med. 90: 379 384. 11. Keely, D., and J. Rees. 1997. New guidelines on asthma management. Aim to control symptoms rapidly, with higher initial doses of steroid and earlier use of agonists. B.M.J. 314:315 316. 12. Agertoft, L., and S. Pedersen. 1994. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir. Med. 88:373 381. 13. Haahtela, T., M. Järvinen, T. Kava, K. Kiviranta, S. Koskinen, K. Lehtonen, K. Nikander, T. Persson, O. Selroos, and A. Sovijarvi. 1994. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N. Engl. J. Med. 331:700 705. 14. Quanjer, Ph., G. J. Tammeling, J. E. Cotes, O. F. Pederson, R. Peslin, and J. C. Yermault. 1993. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Eur. Respir. J. 6(Suppl. 16):5 40. 15. Sears, M. R., D. R. Taylor, C. G. Print, D. C. Lake, G. P. Herbison, and E. M. Flannery. 1992. Increased inhaled bronchodilator vs increased inhaled corticosteroid in control of moderate asthma. Chest 102:1709 1705. 16. Malo, J. L., A. Cartier, N. Merland, H. Ghezzo, A. Barek, J. Morris, and B. H. Jennings. 1989. Four-times-a-day dosing frequency is better than a twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide, to control moderate to severe asthma. Am. Rev. Respir. Dis. 140:624 628. 17. Juniper, E. F., P. A. Kline, M. A. Vanzieleghem, and F. E. Hargreave. 1991. Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate weather improvements in airway responsiveness and clinical asthma are maintained. J. Allergy Clin. Immunol. 87:483 489. 18. Toogood, J. H., J. C. Baskerville, B. H. Jennings, N. M. Lefcoe, and S. A. Johansson. 1982. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J. Allergy Clin. Immunol. 70:288 298. 19. Agertoft, L., and S. Pedersen. Importance of the inhalation device on the effect of budesonide. Arch. Dis. Child. 69:130 133. 20. Fabbri, L. M., P. S. Burge, and L. Croonenburgh. 1993. Comparison of fluticasone proprionate with beclomethasone diproprionate in moderate to severe asthma treated for one year. Thorax 48:817 823. 21. Conolly, A. 1995. A comparison of fluticasone proprionate 100 g twice daily with budesonide 200 g twice daily via their respective powder devices in the treatment of asthma. Eur. J. Clin. Res. 7:15 29. 22. Thorsson, L., S. Edsbacker, and T. B. Conradson. 1994. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur. Respir. J. 7:1839 1844.